A preterm male infant with a patent ductus arteriosus developed neutropenia during treatment with indomethacin. Afterward, the mother described her own history of indomethacin-associated neutropenia. During the recovery from the neutropenia, the infant became septic with bacteremia caused by Enterobacter cloacae. Although indomethacin-related neutropenia has been described in adults, no case in a neonate has been reported. If neutropenia occurs after indomethacin therapy in a neonate, a familial history of indomethacin-associated neutropenia should be sought and the increased risk of infection should be considered.
Introduction
Indomethacin is widely used to close a hemodynamically significant patent ductus arteriosus in preterm infants. 1 Neutropenia associated with indomethacin therapy is infrequent in adults. 2, 3 This indomethacin-related side effect has not been reported in preterm infants. This report describes a mother who had neutropenia associated with indomethacin therapy. Her infant also experienced this complication during use of indomethacin to treat a patent ductus arteriosus.
Case report A 2170 g male infant was born at 32 weeks of gestation by normal spontaneous vaginal delivery. Premature rupture of membranes had occurred 22 h before birth. The healthy 35-year-old mother had received two intrapartum doses of ampicillin; she had no laboratory or clinical evidence of chorioamnionitis. Apgar scores were 9 and 9 at 1 and 5 min, respectively.
An evaluation for infection showed the initial white blood cell count was 10.6 Â 10 3 /mm 3 with a differential of 35% mature neutrophils, 1% bands, 57% lymphocytes and 7% monocytes. The absolute neutrophil count was 3816/mm 3 . At 12 h of life, the infant developed respiratory distress, and a chest radiograph was consistent with the respiratory distress syndrome. As a result of lateonset respiratory distress, congenital pneumonia was suspected, and ampicillin and gentamicin were started. The initial blood culture was negative. A single dose of surfactant improved the infant's status and the infant was taken off assisted ventilation and placed on nasal continuous positive airway pressure on day of life 2.
On day of life 3, an increasing oxygen requirement and a rising PaCO 2 necessitated a return to assisted ventilation. An echocardiogram revealed a hemodynamically significant patent ductus arteriosus. The infant was started on indomethacin and received three doses of 0.2, 0.2 and 0.1 mg/kg given intravenously at 12 h intervals. Ductal closure was successful with this regimen.
Before starting the indomethacin, the WBC was 4.8 Â 10 3 /mm 3 with a differential of 67% mature neutrophils and 4% bands. The absolute neutrophil count was 3408/mm 3 . The day after indomethacin was given, the infant had a white blood cell count of 3.4 Â 10 3 /mm 3 and a differential of 24% mature neutrophils and 2% bands. The absolute neutrophil count was 884/mm 3 . The platelet count was 156 000/mm 3 . Blood, urine and cerebrospinal fluid cultures were obtained. Antimicrobial therapy with vancomycin and cefotaxime were substituted for ampicillin, while treatment with gentamicin was continued. The neutropenia gradually improved, and by day of life 7, the absolute neutrophil count was 1485/mm 3 . The blood, urine and spinal fluid had no microbial growth, and the antibiotics were discontinued on day of life 7. During a discussion with the mother about the sudden decline in her infant's neutrophil count after indomethacin therapy, she revealed complications when she took this drug. The mother had knee discomfort and indomethacin was prescribed by the physician who employed her. Blood work performed shortly after the mother started taking the indomethacin revealed significant neutropenia and the practitioner immediately ordered her to stop the medication. The mother was taking no other medications at this time. The mother's neutrophil count returned to normal within 2 weeks. The mother had no hematologic abnormalities prior to or following this occurrence.
On day of life 9, the infant again developed neutropenia with a WBC 1.3 Â 10 3 /mm 3 with a differential that had 15% mature neutrophils and 3% bands. The absolute neutrophil count was 234/ mm 3 . The infant developed thrombocytopenia for the first time with a platelet count of 83 Â 10 3 /mm 3 . A third blood culture had growth of Enterobacter cloacae that was sensitive to gentamicin, but resistant to third generation cephalosporins. An infectious disease sub-specialist recommended therapy with meropenem and gentamicin. The infant did well thereafter and was discharged on day of life 25.
Discussion
Published reports suggest that an absolute neutrophil count <1000/mm 3 places the infant at significant risk for acquiring an infection. 4, 5 We have presumed that indomethacin-associated neutropenia in this infant may have allowed colonization of respiratory, gastrointestinal, or other body sites with E. cloacae, and thereafter invasive bacterial infection occurred. Indomethacinrelated neutropenia is suggested by the maternal history of indomethacin-associated neutropenia, and the temporal relationship of indomethacin administration and the decline in the infant's absolute neutrophil count.
Neutropenia during the immediate neonatal period is divided into congenital and acquired conditions. [5] [6] [7] Congenital neutropenia caused by reticular dysgenesis, the SchwachmannDiamond syndrome, Kostmann syndrome, and cyclic neutropenia were excluded based on the normal absolute neutrophil count at birth and at discharge. Alloimmune and neutropenia related to maternal autoimmune disease were similarly excluded for the same reason. The mother also did not have chronic hypertension or pre-eclampsia that have been associated with neutropenia at birth. 8 Acquired causes of neutropenia in neonates are most often related to serious systemic infection, while drug-induced neutropenia is an uncommon occurrence. 9 Drug-induced neutropenia secondary to ampicillin and gentamicin administration is unlikely because the absolute neutrophil count was normal when they were being given during the first 48 h of life. Only after indomethacin therapy began did the absolute neutrophil count rapidly decline. Ampicillin-and gentamicininduced neutropenia have not been reported in preterm neonates. Reviews discussing neonatal neutropenia do not mention indomethacin or other non-steroidal anti-inflammatory agents among the causes of neutropenia.
Reports of neonatal infection following indomethacin therapy show an increased risk versus no risk at all. Herson et al. 10 reported the incidence of sepsis in 58 very low birth wight premature infants with patent ductus arteriosus who had been treated with either oral indomethacin or ductal ligation; the study found seven of 31 (22.6%) of the indomethacin-treated infants developed sepsis compared to only one of 27 (3.7%) of those treated with ligation.
All episodes of sepsis occurred within 1 week of therapy. This study did not relate bacterial sepsis in preterm infants to indomethacininduced neutropenia. Conversely, a controlled trial using intravenous indomethacin to close a patent ductus arteriosus found no increase in sepsis among treated versus control infants. 11 A study using prophylactic intravenous indomethacin to prevent intraventricular hemorrhage in preterm infants also found no increased risk of sepsis in infants receiving the drug. 12 No prospective studies have evaluated the risks or the mechanisms that might be associated with bacterial infection following indomethacin administration.
Nonsteroidal anti-inflammatory drugs in general and indomethacin in particular have been associated with neutropenia in adults. 13, 14 The international agranulocytosis and aplastic anemia study group found an odds ratio of 8.9 for indomethacin and agranulocytosis. 15 Drug-induced agranulocytosis is an idiosyncratic reaction and several mechanisms have been proposed. 16 Among the proposed mechanisms, we suggest that destruction of the blood-related neutrophils occurred in this infant because the proportion of mature to immature neutrophils remained the same after exposure to indomethacin. The mechanism, however, remains unknown. A phenomenon that may have promoted bacteremia in this infant is a reduction in tissuerelated neutrophils after blood neutrophils declined. 17 Such a phenomenon would allow bacterial invaders in the respiratory, gastrointestinal, or other sites to move with ease from tissues into the blood stream. In this infant, bacteremia caused by E. cloacae may have occurred via translocation through a bowel wall that had reduced numbers of neutrophils.
In summary, the use of indomethacin may be associated with neutropenia in neonates just as it is in adults. It is important to monitor neutrophil counts in addition to platelet counts when preterm infants receive indomethacin. If neutropenia does occur after indomethacin therapy, a family history of indomethacinassociated neutropenia should be sought. The occurrence of neutropenia following indomethacin administration should heighten awareness of an infectious risk.
